BiotechTube

SerpinPC

Phase 3Terminated
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemophilia a

Conditions

Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor

Trial Timeline

Jul 11, 2024 → Jan 29, 2025

NCT ID
NCT06568302

About SerpinPC

SerpinPC is a phase 3 stage product being developed by Centessa Pharmaceuticals for Hemophilia a. The current trial status is terminated. This product is registered under clinical trial identifier NCT06568302. Target conditions include Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia a were approved

Approved (20) Terminated (3) Active (0)
✅EmicizumabRocheApproved
✅BenefixPfizerApproved
✅Nonacog alfaPfizerApproved
✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved
✅Recombinant Factor IX CoagulationPfizerApproved
✅Moroctocog alfa(AF-CC)PfizerApproved
✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical
17
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06568302Phase 3Terminated
NCT05789537Phase 2Terminated
NCT05789524Phase 2Terminated

Competing Products

20 competing products in Hemophilia a

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
40
EmicizumabChugai PharmaceuticalPhase 3
40
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
40
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
47
EmicizumabChugai PharmaceuticalPhase 3
47
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
40
EmicizumabRochePhase 3
40
HEMLIBRAJohnson & JohnsonPre-clinical
26
EmicizumabRochePhase 3
40
EmicizumabRocheApproved
47
EmicizumabRochePhase 3
44
SPK-8011QQRochePhase 1/2
39
NXT007RochePhase 1/2
39
Emicizumab InjectionRochePhase 2
35
Bypassing Agents + FVIII ReplacementRochePre-clinical
26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
35
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
26
Refacto AFPfizerPre-clinical
18
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
44
ReFacto AFPfizerPhase 3
40